Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed unresectable stage IIIB non-small cell lung cancer~  * Squamous cell carcinoma~ * Adenocarcinoma~ * Large cell carcinoma~ * Non-small cell carcinoma not otherwise specified~* All detectable primary tumor and involved regional lymph nodes must be encompassed by radiotherapy fields~* Measurable disease on 3-dimensional planning CT scan~* No undifferentiated small cell (oat cell or high-grade neuroendocrine) carcinoma~* No stage IV or recurrent disease~* No distant metastases or supraclavicular lymph node involvement~* No significant atelectasis (i.e., atelectasis of an entire lung)~* No pleural effusions, pericardial effusions, or superior vena cava syndrome~* No lung cancer within the past 2 years~* Ineligible for currently open Radiation Therapy Oncology Group (RTOG) phase III lung protocols~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.5 mg/dL~* Aspartate aminotransferase (AST) less than 2 times upper limit of normal~Renal:~* Creatinine no greater than 2.0 mg/dL~Pulmonary:~* Forced expiratory volume (FEV)_1 at least 1.0 L~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No weight loss greater than 5% in the past 6 months~* No other malignancy within the past year except nonmelanoma skin cancer~* Completed 3D plan with total lung V20 \</= 30% mean esophageal dose \</= 34 Gy and esophageal V55 \</= 30%~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior biologic response modifiers for current lung cancer~* At least 5 years since prior biologic response modifiers~Chemotherapy:~* No prior chemotherapy for current lung cancer~* At least 5 years since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy to the thorax~Surgery:~* No prior complete tumor resection

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: 75.25 Gy/36 fx + chemotherapy (Type: EXPERIMENTAL): Phase I: Three-dimensional conformal radiation therapy (3DRT) of 75.25 Gy given in 36 fractions (2.15 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
- Phase I: 74 Gy/37 fx + chemotherapy (Type: EXPERIMENTAL): Phase I: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
- Phase I: 70 Gy/35 fx + chemotherapy (Type: EXPERIMENTAL): Phase I: Three-dimensional conformal radiation therapy (3DRT) of 70 Gy given in 35 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
- Phase II: 74 Gy/37 fx + chemotherapy (Type: EXPERIMENTAL): Phase II: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.

Based on this trial design, predict the completion outcome and termination type (if applicable).